OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY.

D. Van der Heijde, X. Baraliakos, M. Dougados, M. Brown, D. Poddubnyy, F. Van den Bosch, N. Haroon, H. Xu, T. Tomita, L. S. Gensler, M. Oortgiesen, C. Fleurinck, T. Vaux, A. Marten, A. Deodhar. OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY. Annals of the Rheumatic Diseases. 2022 May 23; 81(Suppl 1):12-13.

2022
https://researcherprofiles.org/profile/344526717

D. Van der Heijde, X. Baraliakos, M. Dougados, M. Brown, D. Poddubnyy, F. Van den Bosch, N. Haroon, H. Xu, T. Tomita, L. S. Gensler, M. Oortgiesen, C. Fleurinck, T. Vaux, A. Marten, A. Deodhar